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ABSTRACT: The combination of methotrexate with epidermal growth
factor receptor (EGFR) recombinant antibody, cetuximab, is currently being
investigated in treatment of head and neck carcinoma. As methotrexate
is cleared by renal excretion, we studied the eﬀect of cetuximab on renal
methotrexate handling. We used human conditionally immortalized
proximal tubule epithelial cells overexpressing either organic anion
transporter 1 or 3 (ciPTEC-OAT1/ciPTEC-OAT3) to examine OAT1
and OAT3, and the eﬄux pumps breast cancer resistance protein (BCRP),
multidrug resistance protein 4 (MRP4), and P-glycoprotein (P-gp) in
methotrexate handling upon EGF or cetuximab treatment. Protein kinase
microarrays and knowledge-based pathway analysis were used to predict
EGFR-mediated transporter regulation. Cytotoxic eﬀects of methotrexate
were evaluated using the dimethylthiazol bromide (MTT) viability assay.
Methotrexate inhibited OAT-mediated ﬂuorescein uptake and decreased
eﬄux of Hoechst33342 and glutathione-methylﬂuorescein (GS-MF), which suggested involvement of OAT1/3, BCRP, and MRP4
in transepithelial transport, respectively. Cetuximab reversed the EGF-increased expression of OAT1 and BCRP as well as their
membrane expressions and transport activities, while MRP4 and P-gp were increased. Pathway analysis predicted cetuximab-
induced modulation of PKC and PI3K pathways downstream EGFR/ERBB2/PLCg. Pharmacological inhibition of ERK decreased
expression of OAT1 and BCRP, while P-gp and MRP4 were increased. AKT inhibition reduced all transporters. Exposure to
methotrexate for 24 h led to a decreased viability, an eﬀect that was reversed by cetuximab. In conclusion, cetuximab
downregulates OAT1 and BCRP while upregulating P-gp and MRP4 through an EGFR-mediated regulation of PI3K-AKT and
MAPKK-ERK pathways. Consequently, cetuximab attenuates methotrexate-induced cytotoxicity, which opens possibilities for
further research into nephroprotective comedication therapies.
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■ INTRODUCTION
Current cancer treatments often rely on the administration of
multiple chemotherapeutic drugs to improve overall survival.
These combination therapies can overcome the limitations of
single target drugs, as they exploit diﬀerent action mechanisms
and can be administered under several regimens for curative
and palliative purposes. Recurrent or metastatic squamous
cell carcinoma of the head and neck (SCCHN) yields a poor
prognosis, with limited treatment options, and a novel
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phase I/IIb trial (identiﬁer, NCT02054442; https://clinicaltrials.
gov/) is set to investigate the eﬃcacy and safety of methotrexate
in combination with cetuximab.
Methotrexate is an established antifolate and one of the most
extensively used anticancer agents.1,2 It inhibits the enzyme
dihydrofolate reductase, disrupting DNA synthesis,3 and can be
administered in both high and low doses for the treatment of
autoimmune diseases and cancers.4,5 High-dose methotrexate
(i.e., 12 000 mg/m2) is used in the treatment of malignancy,
while low-dose methotrexate (i.e., 40 mg/m2) is used in meta-
static SCCHN and in various nonmalignant immune-mediated
disorders.6,7 Cetuximab is an antiepidermal growth factor
receptor (EGFR) recombinant monoclonal antibody (IgG1)8
that displays beneﬁcial clinical outcomes in patients with
recurrent or metastatic SCCHN and does not exert renal adverse
eﬀects.9 It binds to the extracellular domain of EGFR and hinders
the ligand-induced tyrosine kinase activation.10 When active,
multiple EGFR tyrosine-kinase domains can trigger downstream
signal transduction cascades, more speciﬁcally the phosphoinosi-
tide 3-kinase (PI3K)-AKT and mitogen activated protein kinase
(MAPK) pathways.11 These pathways are responsible for a series
of intracellular regulatory processes such as cell cycle progression,
neovascularization, migration, diﬀerentiation, proliferation, and
immunogenic responses.12
The kidney, through active tubular secretion, clears a great
variety of chemotherapeutics and among those is methotrexate.
During this process, methotrexate accumulates within the kidney
and, especially at high-dose, the drug can promote extensive
necrosis of the proximal tubular epithelial cells (PTEC).13,14
This is due to transporters expressed in PTEC that are involved
in the excretion process of methotrexate. The drug is eﬃciently
taken up from the blood compartment by the organic anion
transporters 1 and 3 (OAT1−3)15 and excreted into the tubular
lumen by the multidrug resistance proteins (MRP) 2 and 416 and
breast cancer resistance protein (BCRP).17 In general, trans-
membrane transporters are key to renal function and their activity
and expression can be regulated, among others via EGFR.18 In the
kidney, EGFR is expressed in PTEC, and activated by EGF and
EGF-like hormones.19 Furthermore, EGFR can stimulate renal
epithelial regeneration in response to kidney injury.20
Despite the wide use of methotrexate, a potential pharmaco-
kinetic interaction with cetuximab when combined in therapy
is not known. The aim of this study was to investigate the
eﬀects of cetuximab on renal methotrexate handling in vitro
using conditionally immortalized human PTEC overexpressing
either OAT1 or OAT3 (ciPTEC-OAT1/ciPTEC-OAT3).21
Previously, we demonstrated ciPTEC as a representative human
proximal tubule cell line with preserved features, including cell
polarization, monolayer organization, expression of tight junction
proteins, as well as xenobiotic transporter and metabolic enzyme
activities.22−24 Using this cell line, we revealed that cetuximab
downregulates OAT1 and BCRP while it upregulates MRP4 via
EGFR signaling, thereby reducing renal methotrexate uptake
as well as its cytotoxic potential. This appeared to be a common
regulatory pathway, with eﬀects beyond attenuating methotrexate
toxicity, as cisplatin cytotoxicity25 was counteracted as well.
This study shows the nephroprotective potential of combination
therapy, in vitro and opens possibilities for further research on the
use of comedication to manage renal toxicity.
■ METHODS
Chemicals. All chemicals were obtained from Sigma
(Zwijndrecht, The Netherlands) unless stated otherwise.
Stock solutions of all compounds used for transport assays
were prepared according to speciﬁcation in either dimethyl
sulfoxide (DMSO) or dH2O. Cetuximab (Erbitux) was obtained
from Merck Serono (Darmstadt, Germany).
Cell Culture. The ciPTEC-OAT1 and ciPTEC-OAT3 were
cultured in phenol red-free DMEM/F12 (Invitrogen, Breda,
The Netherlands), as previously described. Cells were seeded
at a density of 63 000 cell/cm2, grown for 24 h at 33 °C
and subsequently at 37 °C for 7 days.23,26 ciPTEC required a
temperature shift to mature and grow into fully diﬀerentiated
epithelial cells forming a tight monolayer, prior to each assay.
A detailed composition of the ciPTEC medium can be found in
the Supporting Information (Table S1).
Cetuximab, Methotrexate, and Cisplatin Treatments.
To study the eﬀects of cetuximab, matured ciPTEC were
treated for 24 or 48 h by incubation with or without cetuximab
(500 μg/mL) in culture medium, in the presence or absence
of EGF (10 ng/mL). After cetuximab exposure, cells were
incubated with either increasing concentrations of methotrexate
or cisplatin (up to 100 μM) for 24 h, using standard ciPTEC
culture medium (CM; containing 10% fetal calf serum) or serum-
free medium (SFM). Under normal conditions, ciPTECmedium
contained EGF, which was considered as control condition.
Fluorescent Functional Assays. The retention of
ﬂuorescent substrates was used to determine the changes in
activity of membrane transporters.24 Fluorescein, Hoechst33342,
calcein-AM, 5-chloromethyl ﬂuorescein diacetate (CMFDA),
and (4-(4-(dimethylamino) styryl)-N-methylpyridinium (ASP+)
were used to evaluate the function of OAT1, OAT3, BCRP,
P-gp, MRP4, and OCT2, respectively, as described.21,24 To study
the eﬀect of methotrexate on these transporters, cells were
exposed to a single concentration of the substrates (ﬂuorescein
and calcein-AM, 1 μM; Hoechst33342 and CMFDA, 1.25 μM),
separately, or together with methotrexate. Model inhibitors
probenecid, KO143, MK571, and PSC833 were used to validate
transporter involved. To investigate cetuximab inﬂuence on
transport function, a two-fold step dilution was performed to
obtain a concentration gradient of the ﬂuorescent substrates with
maximum concentrations of 25 μM each. The calcein-AM assay
was performed in the presence of 2.0 μM of inhibitor PSC833
and CMFDA in the presence of 5.0 μM of MK571. Cells were
washed twice before incubation at 37 °C for 10 min
(ﬂuorescein), 30 min (CMFDA, Hoechst33342 and ASP+), or
60 min (calcein-AM), as described previously. Afterward plates
were washed twice and cells were lysed with either 0.1 M NaOH
(ﬂuorescein) or Triton-X100 1% (calcein-AM and CMFDA).
Subsequently, ﬂuorescence was acquired via an Ascent
Fluoroskan FL microplate reader (appropriate ﬁlter settings:
wavelengths, ﬂuorescein, calcein, and glutathione-methyl ﬂuo-
rescein (GS-MF: the end-metabolites of calcein-AM and
CMFDA, respectively); excitation, 494 nm; emission, 512 nm.
Hoechst33342: excitation, 350 nm; emission, 461 nm. ASP+:
excitation, 470 nm; emission, 590 nm). A schematic representa-
tion of the interactions between ﬂuorescent substrates andmodel
inhibitors is depicted in the Supporting Information (Figure S1).
Gene Expression. Transporters gene expression proﬁling
was performed by isolating total RNA from cells grown in
six-well plates, using an RNeasy Mini kit (Qiagen, Venlo, The
Netherlands), according to the manufacturers speciﬁcations.
Subsequently, cDNA was synthesized using the Omniscript
RT-kit (Qiagen). Subsequently, quantitative PCRwas performed
in a CFX96 real-time PCR detection system (Biorad, Veenendaal,
The Netherlands). GAPDH was used as housekeeping gene
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for normalization, and its expression was not aﬀected by the
experimental conditions tested as demonstrated in the Support-
ing Information (Figure S2). Relative expression levels were
calculated as fold change using the 2−ΔΔCT method. The
primer-probe sets were obtained from Applied Biosystems:
GAPDH - hs99999905_m1; BCRP - hs00184979_m1; MRP4 -
hs00195260_m1 and Pgp - hs00184500_m1; OAT1 -
hs00537914.
Western Blot Analysis. The protein levels of OAT1 and
BCRP were determined by Western blotting using 9% (W/V)
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Cell samples were homogenized in ice-cold Tris-Sucrose
(TS) buﬀer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4)
containing protease inhibitors (PMSF 100 μM, Aprotinin
5 μg/mL, Leupeptin 5 μg/mL, Pepstatin 1 μg/mL, E64 10 μM).
Membrane fractions were obtained by high shear passage using a
microﬂuidizer LV1 (Microﬂuidics, Westwood, AM, USA), and cell
lysates were span for 20 and 90 min at 4000 and 25 000 rcf at 4 °C,
respectively. Membranes were incubated with mouse anti-BCRP
(1:200 dilution; Abcams, Cambridge, UK) and rabbit anti-OAT1
antibody (1:100 dilution; Abcams, Cambridge, UK) overnight
at 4 °C. As a loading control, rabbit anti-Na, K-ATPase antibody
(α-subunit, 1:4000 dilution, C356-M09,27) was used. Secondary
antibodies, Alexa ﬂuor 680 goat antirabbit IgG (1:10 000 dilution;
Life Technologies Europe BV), streptavidin Alexa ﬂuor 680
(1:10 000 dilution; Life Technologies Europe BV), and IRDye
800 goat antirabbit IgG (1:10 000 dilution; Rockland, PA).
Fluorescence was detected using the Odyssey scanner CLx
(Li-Cor Biosciences, USA). Data were normalized to protein
expression levels of the loading control using ImageJ software
(imagej.nih.gov).
Serine/Threonine and Tyrosine Kinase Microarrays
and Pathway Analysis. To investigate downstream cetuximab
eﬀects on ciPTEC, the serine/threonine kinase (STK) and
protein tyrosine kinase (PTK) activity proﬁles were determined
with 3D dynamic peptide microarrays. Using the PamStation12
platform and PamChip microarrays, containing four identical
arrays each, with 142 either STK or PTK immobilized phos-
phorylation sites, cetuximab treated ciPTEC samples were
analyzed as previously described.28 Cells were grown in six-well
plates, and after maturation, cells were washed and incubated
with cetuximab either in the presence or absence of EGF for
15 min in HBSS. Cell pellets were lysed using mammalian
protein extraction reagent (MPER) in the presence of HALT
phosphatase and protease inhibitors (Pierce) according to
manufacturer instructions. Resulting cell lysates were proﬁled
as described previously.29,30 The data were analyzed using Evolve
and BioNavigator (signal acquisition and data analysis software,
respectively; Pamgene) to generate heat maps and diﬀerential
kinase activity hits by comparing ratios over the control
condition (+EGF). Signiﬁcantly relevant peptide phosphoryla-
tions (targets/hits) were selected and used to generate canonical
pathway signaling hypotheses by performing an unbiased
analysis using the Genego MetaCore (thomsonreuters.com)
software and database resources.
Intracellular Methotrexate Metabolite Quantiﬁcation
by LC−MS/MS. To determine methotrexate uptake by ciPTEC,
the intracellular levels of methotrexate polyglutamates were
analyzed following 48 h cetuximab pretreatment and 24 h
methotrexate exposure in both CM and SFM. Cells were washed,
harvested and cell pellets were frozen in liquid nitrogen and
stored at −80 °C prior to analysis. Samples were analyzed as
previously described.31 Brieﬂy, 16% perchloric acid was used
to precipitate protein, after a centrifugation step, 10 μL (per
sample) of supernatant was analyzed by liquid chromatography-
electrospray ionization-tandem mass spectrometry (UPLC−
ESI−MS/MS) using a Waters Acquity BEH C18 column and
a 5−100% gradient of 10 mM ammonium bicarbonate pH10
and methanol on a classic Acquity UPLC (Waters Instruments).
Detection was performed during a 6 min run by positive
electrospray ionization using a Quattro Premier XE (Waters
Instruments).
Cell Cycle Analysis. For cell cycle analysis, cells were grown
in six-well plates, and following treatment cells were harvested
using accutase, washed, and centrifuged before ﬁxation with cold
70% (v/v) ethanol for 1 h. Subsequently, the cells, in suspension,
were stained with a propidium iodide (PI) solution containing
40 μg/mL PI, 100 μg/mLRNase A, and 0.1% (v/v) Triton X-100
for 45 min. The data were retrieved using a BD FACSCanto II
ﬂow cytometer and analyzed using the FlowLogic software
(Chromocyte, Sheﬃeld, UK).
Cell Viability. Cell survival upon methotrexate or cisplatin
exposure was determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. Cells were washed
twice and incubated with 5 mg/mL MTT (100 μL p/well) for
a minimum of 2 h at 37 °C; after washing, wells are dissolved in
200 μL of DMSO (p/well) and absorbance read via a BioRad
iMark microplate reader (absorbance: 550−600 nm). Cisplatin
toxicity was also evaluated by the Presto-blue (PB) assay, and
cells were incubated for 1 h with 1:10 dilution PB solution
(100 μL p/well) at 37 °C. Subsequently, the supernatant was
transferred to a 96-well plate and absorbance read using Jasco
FP8300 Spectrophotometer (excitation wavelength, 560 nm;
emission wavelength, 590 nm).
Data Analysis. Transport activity was calculated by normal-
izing ﬂuorescence intensity, expressed in arbitrary units (a.u.),
to baseline values (no inhibitor) after background subtraction,
as described.24 Inhibition of eﬄux activity led to increased total
ﬂuorescence; therefore, eﬄux activity was depicted as the inverse
of the fold increase in ﬂuorescence. Nonlinear analysis according
to Michaelis−Menten kinetics was performed using GraphPad
Prism 5.02 (GraphPad software, SanDiego, CA, USA). Diﬀerences
between groups were considered to be statistically signiﬁcant
when p < 0.05 using a one-tailed Student’s t test. All data are
presented as mean ± SEM.
■ RESULTS
Renal Excretion of Methotrexate Is Mediated by OAT1,
OAT3, BCRP, and MRP4. Methotrexate clearance has been
studied in humans and rodents in vivo and in cell lines expressing
a single transporter; however, its handling in a renal cell model
containingmultiple relevant transporters has not been performed.
We ﬁrst examined the renal excretion route for methotrexate
in ciPTEC-OAT1 and ciPTEC-OAT3 in an indirect way by
measuring the interaction of methotrexate with marker substrates
ﬂuorescein, GS-MF and Hoechst33342 for OAT1/OAT3,
MRP’s and BCRP, respectively.21,24 Model inhibitors were used
as positive control and the ﬂuorescence levels without inhibition
were normalized to 100%. Upon methotrexate exposure, OAT1,
BCRP, and MRP’s activities were signiﬁcantly reduced in
ciPTEC-OAT1, whereas in ciPTEC-OAT3, only OAT3 and
MRP4 activities were reduced (Figure 1A−C). BCRP inhibition
could not be determined in ciPTEC-OAT3 and P-gp activity was
not aﬀected in both cell lines (Figure 1D). These results conﬁrm a
renal excretion pathway previously suggested (Figure 1E).
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Cetuximab Regulates Tubular Xenobiotic Transport.
Next, renal drug transporter expression and its activity were
determined after treating ciPTEC with cetuximab. Exposure to
cetuximab for 48 h resulted in an altered expression and function
of all major transport systems present in ciPTEC-OAT1 as
compared to the standard culture conditions in the presence of
EGF, but not OAT3. Therefore, subsequent experiments were
performed with ciPTEC-OAT1. The gene expression of OAT1
was reduced in the absence of EGF or in the presence of
cetuximab, which was also observed for BCRP (Figure 2A,C).
In agreement, protein expression levels of OAT1 and BCRPwere
reduced in the absence of EGF (Figure 2A,C). Both MRP4 and
P-gp mRNA levels were increased in the absence of EGF as well
as in the presence of cetuximab (Figure 2E,G), for which we
could not determine quantiﬁable diﬀerences in their expressions
using the sample preparation methodology described. The
accumulations of ﬂuorescein, Hoechst33342, calcein, and GS-MF
were reduced upon cetuximab exposure both in the presence or
absence of EGF (Figure 2B,D,F,H). This eﬀect was similar to that
observed after culturing cells for 48 h in absence of EGF.
Figure 1. Methotrexate uptake in ciPTEC-OAT1 and ciPTEC-OAT3. Methotrexate (MTX) signiﬁcantly reduced the uptake of ﬂuorescein (A) and
inhibited the eﬄux of Hoechst33342, in ciPTEC-OAT1 (B) and GS-MF (C), in both ciPTEC-OAT1 and OAT3. Calcein eﬄux was not blocked by
methotrexate in both cell lines (D), and Hoechst33342 activity in ciPTEC-OAT3 could not be determined. Model inhibitors Probenecid, KO143,
MK571, and PSC833 were tested as positive controls. Data are presented as mean values ± SEM. Statistical analysis was performed via unpaired
Student’s t test. ∗, p < 0.05 and ∗∗∗, p < 0.01 compared to control (CTRL). A schematic depiction of the potential interactions (E).
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Figure 2. Expression and function of renal drug transporters upon cetuximab pretreatment. Cells were pretreated with cetuximab (CTX) before gene
and protein expression was determined. The activity of renal drug transporter was evaluated using ﬂuorescent substrates (OAT1, ﬂuorescein; BCRP,
Hoechst33342; P-gp, calcein and MRP4; GS-MF, respectively). Changes in transport activity are depicted in ﬂuorescent intensity expressed in arbitrary
units (a.u). CTX eﬀectively reduced the expression and activity of OAT1 (A, B) and BCRP (C, D), while increasing the expression and activity of P-gp
(E, F) and MRP4 (G, H). Protein expression was determined for OAT1 (60 kDa) and BCRP (72 kDa) (A, C lower panel), Na,K-ATPase was used as
loading control (112 kDa). Data are presented as mean values ± SEM, n = 3. Statistical analysis was performed via unpaired Student’s t test. ∗, p < 0.05
and ∗∗∗, p < 0.01 compared to control (+EGF condition).
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When cetuximab was given in absence of EGF, no further
alterations were observed. Functional changes were evidenced
from the accumulation of the ﬂuorescent probes, in which a
higher intensity yielded more accumulation of the probe. For
eﬄux pumps, a higher activity yielded a reduction in substrate
accumulation given an increased rate of removal, as was observed
for GS-MF and calcein. The reduction in BCRP was not
reﬂected by an increased Hoechst33342 retention, most likely
due to the increased expression in P-gp, which can also secrete
Hoechst33342.24 After nonlinear regression analysis according
to Michaelis−Menten kinetics, parameters were calculated and
presented in Table 1.
No signiﬁcant changes in IC50 values were found for all
conditions tested (Table 1), implicating that the results observed
relate to changes in expression levels of the transporters rather
than changes in aﬃnities.
Cetuximab Activates Serine/Tyrosine Signaling Down-
stream of EGFR. To investigate the downstream eﬀects of
cetuximab-EGFR signaling in ciPTEC-OAT1, kinase activity
proﬁling using peptide microarrays comprising either 144 PTK
or STK phosphosite was performed (PamChip) and used to
generate an interaction network. Cells were treated with
cetuximab for 15 min in the presence and absence of EGF.
Overall, cetuximab activated PTK and STK. In the presence of
EGF, STK activity decreased, an eﬀect that was counteracted by
cetuximab coincubation (Figure 3A). The absence of EGF
sustained a similar eﬀect to that of CTX and both conditions did
not yield an additive eﬀect in transport activity. This illustrates
that the same regulatory mechanism is triggered and involved
in the response and maximally aﬀected by either one alone
(Figure S3). Subsequently, signiﬁcantly modulated targets
(phosphorylated peptides) were selected and evaluated with the
MetaCore software. Analysis provided a list of known pathways
that most signiﬁcantly overlap with the PTK and STK targets
determined for cetuximab. Results show that the signaling
pathways triggered by cetuximab mainly involve tyrosine kinases,
while EGF mostly aﬀects serine kinases, underlining the stark
diﬀerences between both conditions. An in-depth scrutiny
into the predicted pathways (Figure 3C) revealed that in the
control condition (+EGF) the key regulatory elements are cAMP-
dependent protein kinase A (PKA), serine/threonine speciﬁc
kinase C (PKC), downstream transcription factor Creb1 (cAMP
responsive element binding protein 1), and the nuclear factor
kappa light polypeptide gene enhancer (NF-kβ1). On the other
hand, cetuximab exposure reduced EGFR, receptor tyrosine-
protein kinase (Erbb2) and PKC activity, while enhancing
phospholipase C-γ (PLCγ), phosphatidylinositol-4,5-bisphos-
phate 3-kinase (P13K), and phosphoinositide dependent protein
kinase (PDK). There was also a direct link between EGFR
inhibition and MRP4 enhanced phosphorylation. Additional
results from the kinomic and pathway analyses are presented as
Supporting Information. Further down, EGFR signal trans-
duction targeted the AKT and MAPK/ERK pathways implicated
in regulating the expression of OAT1, BCRP, P-gp, and MRP4.
When cells were exposed to LY294002, an AKT inhibitor, the
expression of all transporters was reduced (Figure 3D), whereas
the ERK inhibitor U-0126 reduced the expression of OAT1
and BCRP and upregulated the expression of P-gp and MRP4
(Figure 3B).
Cetuximab Reduces Methotrexate Uptake and Ameli-
orates Cytotoxicity. Although high-dose methotrexate appears
to be nephrotoxic in vivo, ciPTEC-OAT1 were only moderately
sensitive to methotrexate, with a reduction in cell viability of
about 70−80% at the highest concentration tested (Figure 4).
In agreement with its eﬀect on the functional expression of the
renal drug transporters, a 24 h cetuximab pretreatment eﬀectively
reduced the intracellular concentration of methotrexate-
polymglutamate 1 (Figure 4A). Cell cycle analysis showed that
after 48 h cetuximab treatment, G0/G1 phase (resting phase)
increased from 75 ± 4% to 81 ± 6% (Figure 4B). A similar eﬀect
as observed when cells were cultured in the absence of EGF
(Figure 4C). When exposed to increasing concentrations of
methotrexate, ciPTEC viability reduced as measured by
mitochondrial activity (Figure 4D). However, when cells were
exposed for 24 h to 100 μM methotrexate followed by a 24 h
recovery period, the reduction in cell viability was reversed. This
was independent of cetuximab treatment (Figure 4E). In cells
treated with cetuximab for 24 h prior to a 48 h methotrexate
treatment, the toxic eﬀects of methotrexate could be prevented.
A similar eﬀect was observed after 24 h pretreatment with the
ERK inhibitor, U-0126 (Figure 4F). This preventive eﬀect of
CTX was not observed in the ciPTEC-OAT3 line (Figure 4G),
which suggested further that this transporter is not regulated
through EGFR signaling.
EGFR-Mediated Signaling Is Also Involved in Cisplatin-
Induced Cytotoxicity. To investigate whether the attenuation
in toxicity by cetuximab was speciﬁc for methotrexate or a more
common phenomenon in tubule epithelial cells, we investigated
the role of EGFR signaling on cisplatin-induced cytotoxicity.
Cisplatin is another agent used in SCCHN combination therapy
that, unlike methotrexate, is taken up by PTEC via the organic
cation transporter 2 (OCT2) and can lead to programmed cell
death.32 Similar to the eﬀect observed for methotrexate, pretreat-
ment with cetuximab for 24 h ameliorated cisplatin-induced
toxicity. Cisplatin treatment alone reduced viability to 64 ± 5%,
and when preceded by cetuximab, viability was maintained
at 91 ± 10% (Figure 5A). Increasing concentrations of cisplatin
resulted in a severe loss of mitochondrial activity in ciPTEC-
OAT1, where a maximum concentration of 100 μM resulted in
near total activity loss after 6 h exposure followed by a 72 h
recovery period. Cetuximab pretreatment did not exert any
tangible eﬀect on cell viability. On the other hand, the absence
Table 1. Nonlinear Regression Analysis of Transport Activity of Fluorescent Substrates after 48 h Exposure to Cetuximab in
ciPTEC-OAT1a
+EGF −EGF +EGF+CTX −EGF+CTX
Km (μM) Vmax (a.u.) Km (μM) Vmax (a.u.) Km (a.u.) Vmax (a.u.) Km (μM) Vmax (a.u.)
Fluorescein 4.3 ± 0.5 14.7 ± 0.5 5.6 ± 0.5 9.6 ± 0.3 5.1 ± 0.6 9.4 ± 0.4 5.4 ± 0.8 8.2 ± 0.5
Hoechst 33342 21.3 ± 4.3 108.7 ± 8.1 23.8 ± 4.6 81.0 ± 6.0 19.15 ± 4.3 82.7 ± 6.6 22.4 ± 4.3 76.2 ± 5.5
Calcein-AM 36.8 ± 6.3 378.7 ± 43.6 38.4 ± 6.7 272.8 ± 32.4 22.4 ± 3.3 209 ± 18.0 22.7 ± 3.8 178.3 ± 17.5
CMFDA 20.2 ± 1.5 436.5 ± 18.1 17.5 ± 1.6 296.6 ± 14.8 13.0 ± 1.6 267.2 ± 15.8 13.5 ± 1.4 250.4 ± 13.1
aData are expressed as mean values ± SEM of a minimum of two independent assays performed in triplicate. Transport activity is depicted in
ﬂuorescent intensity, expressed in arbitrary units (a.u).
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of EGF resulted in reduced cisplatin toxicity compared to the
condition with EGF, revealing TC50 values of 44 ± 10 μM
compared to 32 ± 18 μM, respectively (Figure 5B). Further-
more, the uptake of ASP+, a well-known OCT2 model substrate,33
decreased upon cetuximab treatment (Figure 5C), which suggested
that the transporter is regulated through EGFR signaling as well.
■ DISCUSSION
In the present study, we revealed the mechanistic interactions
between methotrexate and cetuximab aﬀecting renal metho-
trexate transport activity and cytotoxic potency. Our results show
that cetuximab changes drug transporter function through EGFR
signaling in proximal tubule cells. The changes in transport
activity attenuated the toxic eﬀects of methotrexate and cisplatin.
These ﬁndings shed light on the potential of using EGFR
signaling modulation as a target to prevent renal toxicity in
combination chemotherapy.
Nephrotoxicity is a major concern in various chemo-
therapeutic regimens, and often a dose-limiting factor. The
delayed elimination of methotrexate in the course of high-dose
methotrexate chemotherapy leads to a considerable accumu-
lation of the drug in proximal tubules, greatly exceeding plasma
levels up to 100-fold.34 Severe renal toxicity is hence derived from
the intratubular precipitation of methotrexate crystals, despite its
antifolate properties.35
In proximal tubules, xenobiotic transporters play a key role in
drug excretion and disposition. Acting as selective carriers, they
remove the majority of xenobiotics and protein-bound drugs
from the bloodstream.36 We demonstrated competition between
methotrexate and ﬂuorescein for OAT1/OAT3-mediated
uptake. Upon entering the cells, methotrexate is metabolized
through the addition of glutamate residues by folylpolygluta-
mate-synthetase,37 of which methotrexate-polyglutamate 1 was
measured intracellularly. Furthermore, we conﬁrmed that
BCRP as well as MRP4 are involved in cellular excretion of
methotrexate, demonstrating that its renal tubular excretion
pathway suggested can be mimicked in vitro using ciPTEC.38
Cetuximab inﬂuences the activity of renal uptake as well as
eﬄux transporters involved in methotrexate excretion, except
for OAT3. Cetuximab downregulated OAT1 and BCRP, while
upregulating MRP4 and P-gp, predominantly through ERK
mediated signaling downstream EGFR. The receptor is highly
expressed in renal tubular cells and key to their physiology,
as demonstrated by its involvement in, for example, electrolyte
homeostasis by adjusting trans-epithelial resistance and tight-
function conﬁguration, and controlling sodium and magnesium
reabsorption.39 Changes in gene expression of the transporters
after cetuximab exposure are reﬂected by their protein levels and,
subsequently, at the functional level as a result of a transcriptional
regulation of the transport systems. Moreover, cetuximab treat-
ments showed parallels with the eﬀects determined in the absence
of EGF, further specifying the role of EGFR in renal xenobiotic
transporter regulation.
By kinomic and pathway analysis,40 we determined that under
standard culturing conditions (in the presence of EGF), the
main signaling pathways involve STK activity resulting in the
regulation of PKC and PKA. In line with our ﬁndings, activation
of PKC has previously been shown to aﬀect cellular distribution
of OAT1 by promoting ubiquitination of the transport protein.
This results in an accelerated internalization of the transporter
from cell surface to intracellular compartments and a reduction
in Vmax.41−44 Similarly, OCT2 activity can be modulated by a
phosphor-tyrosine switch and stimulation by EGF is abolished by
MAPK and PKA inhibition.45,46 Moreover, BCRP expression can
be regulated by the axis EGFR− AKT − ERK − CREB, whereas
P-gp function and membrane traﬃc are dependent on PKC and
PKA-mediated phosphorylation.47,48
Cetuximab treatment led to an extensive shift in the kinase-
mediated signaling cascades, most dominantly on PTK activity
(thus upstream or initial signaling). Pathway analysis of the
signiﬁcant activity modulations indicated the involvement of PLC
and PI3K, underlying the role of phospholipases in this pathway,
leading to modulation of PKC and PDK. Here, the PI3K-AKT
pathway reporting phosphosites indicated downregulation of the
mechanistic target of rapamycin (mTOR) kinase and eukaryotic
translation initiation factor 4E (eIF4E). In a seemingly reductant
route, PLC-mediated PKC downregulation also results in
RAS-mediated ERK and MAPK downregulation. The network
of interactions predicted for cetuximab action in ciPTEC-OAT1
are in line with what has been previously described in cancer
Figure 3. Cetuximab-mediated regulation of EGFR downstream
signaling. Cetuximab (CTX) promoted the activation of STK and
phospholipases leading to PI3K-AKT and MAPK-ERK regulation of
renal drug transporters. Data in panel B is expressed as mean values ±
SEM of a minimum of two independent assays performed in triplicate.
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models.49 Inhibition of AKT and ERK changed the expression of
OAT1, BCRP, MRP4, and P-gp in the same fashion as when cells
were exposed to cetuximab, further implicating these pathways
in regulating the activity of renal drug transporters (Figure 3C).
The modulation of transcription factors (Creb1, NFKβ, eIF4E)
revealed in our analysis could hypothetically account for the
transcriptional changes in expression observed after 48 h exposure
to cetuximab.
Renal methotrexate uptake is described to be handled primarily
by OAT3.50,51 Here we show that OAT1 can also play a role in
Figure 4. Cetuximab reduced methotrexate-induced cytotoxicity in ciPTEC-OAT1. Exposure to cetuximab (CTX) for 24 h reduced the uptake of
methotrexate (MTX) in both CM (A) and SFM (B). CTX pretreatment eﬀectively rests cell cycle progression (C). For cell viability assessments, cells
were exposed to methotrexate (0−100 μM) for 24 h in SFM (D), MTX (100 μM) for 24 h in SFM, followed by 24 h of treatment with CM (E) or CTX.
Cells were preconditioned for 24 h in SFM with CTX or U-0126 (2 μM), followed by 48 h of exposure to MTX (100 μM) (F). MTT assay was then
performed. CTX preconditioning did not rescue MTX cytotoxicity in ciPTEC-OAT3 (G). Results are expressed in viability (%) compared to control
(i.e., SFM-treated cells). CTX pretreatment eﬀectively reduced MTX uptake and toxicity. Values are shown as mean ± SEM of minimally two
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methotrexate uptake and its cytotoxicity. The role of EGF in
regulating both basolateral and apical transporters underlines how
the combined activities of diﬀerent drug transporters impacts
methotrexate distribution beyond the activity of a predominant
pump. Further, this mechanism may be seen as part of broader
physiological response. EGF is an important renal growth factor
and can be of both systemic or renal origin.39,52 Modifying
renal drug excretion via EGFR signaling could, hypothetically,
be promoted by systemic EGF originating from another organ
system as response to a toxic event. Regulatory mechanisms
involving both SLC and ABC transporters have been proposed to
determine the whole-body distribution of metabolites, nutrients
and xenobiotics,53−55 and our ﬁndings suggest that EGFR
regulation could inﬂuence drug distribution by modulating both
transport systems.
Although high-methotrexate doses have been reported
nephrotoxic, methotrexate toxicity in proximal tubule cells
in vitro is limited. This is partly explained by the absence of a
tubular lumen in which methotrexate can precipitate leading to
tubular obstruction and eventually tubulopathy.35 Moreover,
ciPTEC-OAT1 are matured diﬀerentiated cells that show little
proliferation which contributes further to the reduced sensitivity
to methotrexate, as the drug preferentially targets proliferating
and actively dividing cells. Nonetheless, cetuximab pretreatment
prevented methotrexate-induced toxicity in cells grown without
serum. Under serum deprivation conditions cell cycle progression
can be stimulated,56 which sensitized the cells to methotrexate.
Pretreatment with U-0126 also prevented methotrexate-related
toxicity, re-enforcing the role EGFR mediated MAPK/ERK
signaling plays in nephrotoxicity by regulating transport activity in
the proximal tubule. Noteworthy, ciPTEC-OAT1 are immortal-
ized and transduced to overexpress OAT1, which may have
implications for its active regulatory pathways in this cell model.
Nonetheless, our pathway analysis is consistent with previously
reported results with respect to the regulation of drug transporters.
Remarkably, in the ciPTEC-OAT3 line, equally sensitive to
methotrexate, cetuximab did not recover cytotoxicity in contrast
to the observations in ciPTEC-OAT1. This may be indicative
of separate regulatory mechanisms for OAT1 and OAT3 or a
consequence of the transduction of OAT3 in ciPTEC.21
The consequences of EGFR cascades inhibition with positive
outcomes for renal damage have been reported previously in rats
in vivo.57 Here, we provide direct evidence implicating EGFR
in drug transport regulation through PKA and PKC signaling,
thereby suppressing methotrexate cytotoxicity in vitro. This
protective eﬀect is not limited to methotrexate, as we show that
cisplatin cytotoxicity25 was also suppressed in our model, which
further conﬁrms the positive impact of PKA and PKC signaling in
drug-induced renal damage. While cetuximab combined with
cisplatin improves cancer treatment outcome,58 improved
eﬃcacy of cetuximab combined with low-dose methotrexate is
under investigation. This study underlined the implications for
drug distribution by showing pronounced changes in transport
activity promoted by cetuximab, in particular at the eﬄux
Figure 5. Cetuximab reduced cisplatin-induced cytotoxicity. Cell viability in the presence of cisplatin (CDDP) was determined after cetuximab (CTX)
pretreatment for 24 h in SFM, followed by exposure to CDDP (25 μM) for 24 h.MTT assay was then performed (A). Preconditioning of cells with CTX
decreased CDDP cytotoxicity. Results are expressed in viability (%) compared to control (i.e., SFM-treated cells). CDDP toxicity after 72 h recovery in
CM and CTX was determined after 48 h CTX pretreatment followed by 6 h of increasing CDDP concentrations (0−100 μM) (B). CDDP recovery was
performed in CM to minimize cell stress. The absence of EGF ameliorated CDDP toxicity. The accumulation of ASP+ (OCT2 substrate) was reduced
upon CTX pretreatment (C). Values are shown as mean ± SEM of minimally two independent experiments performed in triplicates. ∗, Signiﬁcantly
diﬀerent from control (p < 0.05).
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side of proximal tubule cells. Further research into the eﬀects
of comedication and its inﬂuence on the renal excretion of
nephrotoxic agents can elucidate about the use of combination
therapies to manage and prevent nephrotoxicity.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the ACS
Publications website at DOI: 10.1021/acs.molpharmaceut.7b00308.
ciPTEC culture medium formulation; pathways identiﬁed
as signiﬁcant matches to kinase phosphorylation sites
obtained from PTK/STK PamChip array; graphic abstract
of “Fluorescence-Based Transport Assays Revisited in a
Human Renal Proximal Tubule Cell Line”; Ct values for
GAPDH in diﬀerent experimental conditions; cetuximab
inhibition of the EGFR phosphosite; metacore knowl-
edge-based pathway analyses of eﬀect of EGF or EGF
together with cetuximab on ciPTEC-OAT1; pathway
analysis symbols key (PDF)
■ AUTHOR INFORMATION
Corresponding Author





The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
This work was supported by the Nephrotools consortium under
the scope of EU FP7 Marie Curie actions (Grant No. 289754)
and a Dutch Kidney Foundation grant (Grant No. KJPB 11.023).
We thank Milos Mihajlovic and Sam Hariri for their insight and
assistance with the FACS analysis performed for this study, and
Ola Haj Mustafa for the help in the OTA3 experiments.
■ REFERENCES
(1) Jolivet, J.; Cowan, K. H.; Curt, G. A.; Clendeninn, N. J.; Chabner, B.
A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med.
1983, 309 (18), 1094−1104.
(2) Bleyer, W. A. Methotrexate: clinical pharmacology, current status
and therapeutic guidelines. Cancer Treat. Rev. 1977, 4 (2), 87−101.
(3) Rajagopalan, P. T.; Zhang, Z.; McCourt, L.; Dwyer, M.; Benkovic,
S. J.; Hammes, G. G. Interaction of dihydrofolate reductase with
methotrexate: ensemble and single-molecule kinetics. Proc. Natl. Acad.
Sci. U. S. A. 2002, 99 (21), 13481−13486.
(4) Murakami, T.; Mori, N. Involvement of Multiple Transporters-
mediated Transports in Mizoribine and Methotrexate Pharmacoki-
netics. Pharmaceuticals 2012, 5 (8), 802−836.
(5) Bright, R. D. Methotrexate in the treatment of psoriasis. Cutis.
1999, 64 (5), 332−334.
(6) Holmboe, L.; Andersen, A. M.; Morkrid, L.; Slordal, L.; Hall, K. S.
High dose methotrexate chemotherapy: pharmacokinetics, folate and
toxicity in osteosarcoma patients. Br. J. Clin. Pharmacol. 2012, 73 (1),
106−114.
(7) Ashtari, F.; Savoj, M. R. Effects of low dose methotrexate on
relapsing-remitting multiple sclerosis in comparison to Interferon beta-
1alpha: A randomized controlled trial. J. Res. Med. Sci. 2011, 16 (4),
457−462.
(8) Ciardiello, F.; Tortora, G. EGFRAntagonists in Cancer Treatment.
N. Engl. J. Med. 2008, 358 (11), 1160−1174.
(9) Cosmai, L.; Gallieni, M.; Porta, C. Renal toxicity of anticancer
agents targeting HER2 and EGFR. J. Nephrol. 2015, 28 (6), 647−57.
(10) Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the
complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5 (5), 341−54.
(11) Citri, A.; Yarden, Y. EGF-ERBB signalling: towards the systems
level. Nat. Rev. Mol. Cell Biol. 2006, 7 (7), 505−516.
(12) Pozzi, C.; Cuomo, A.; Spadoni, I.; Magni, E.; Silvola, A.; Conte, A.;
et al. The EGFR-specific antibody cetuximab combined with chemo-
therapy triggers immunogenic cell death. Nat. Med. 2016, 22 (6), 624−
631.
(13) Zhao, S.; Chen, C.; Liu, S.; Zeng, W.; Su, J.; Wu, L.; et al. CD147
promotes MTX resistance by immune cells through up-regulating
ABCG2 expression and function. J. Dermatol. Sci. 2013, 70 (3), 182−
189.
(14) Dabak, D. O.; Kocaman, N. Effects of silymarin on methotrexate-
induced nephrotoxicity in rats. Renal Failure 2015, 37 (4), 734−739.
(15) Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.;
Hosoyamada, M.; Cha, S. H.; et al. Characterization of methotrexate
transport and its drug interactions with human organic anion
transporters. J. Pharmacol. Exp. Ther. 2002, 302 (2), 666−671.
(16) Garcia, R.; Franklin, R. A.; McCubrey, J. A. EGF induces cell
motility and multi-drug resistance gene expression in breast cancer cells.
Cell Cycle 2006, 5 (23), 2820−2826.
(17) zu Schwabedissen, H. E. M.; Grube, M.; Dreisbach, A.;
Jedlitschky, G.; Meissner, K.; Linnemann, K.; et al. Epidermal growth
factor-mediated activation of the map kinase cascade results in altered
expression and function of ABCG2 (BCRP). Drug Metab. Dispos. 2006,
34 (4), 524−533.
(18) Liu, N.; Wang, L.; Yang, T.; Xiong, C.; Xu, L.; Shi, Y.; Bao, W.;
Chin, Y. E.; Cheng, S. B.; Yan, H.; Qiu, A.; Zhuang, S. EGF Receptor
Inhibition Alleviates Hyperuricemic Nephropathy. J. Am. Soc. Nephrol.
2015, 26 (11), 2716−2729.
(19) Tang, J.; Liu, N.; Zhuang, S. Role of epidermal growth factor
receptor in acute and chronic kidney injury. Kidney Int. 2013, 83 (5),
804−810.
(20) Flamant, M.; Bollee, G.; Henique, C.; Tharaux, P. L. Epidermal
growth factor: a new therapeutic target in glomerular disease. Nephrol.,
Dial., Transplant. 2012, 27 (4), 1297−1304.
(21) Nieskens, T. T.; Peters, J. G.; Schreurs, M. J.; Smits, N.;
Woestenenk, R.; Jansen, K.; et al. A Human Renal Proximal Tubule Cell
Line with Stable Organic Anion Transporter 1 and 3 Expression
Predictive for Antiviral-Induced Toxicity. AAPS J. 2016, 18 (2), 465−
475.
(22) Mutsaers, H. A.; Wilmer, M. J.; Reijnders, D.; Jansen, J.; van den
Broek, P. H.; Forkink, M.; et al. Uremic toxins inhibit renal metabolic
capacity through interference with glucuronidation and mitochondrial
respiration. Biochim. Biophys. Acta, Mol. Basis Dis. 2013, 1832 (1), 142−
150.
(23) Jansen, J.; Schophuizen, C. M.; Wilmer, M. J.; Lahham, S. H.;
Mutsaers, H. A.; Wetzels, J. F.; et al. A morphological and functional
comparison of proximal tubule cell lines established from human urine
and kidney tissue. Exp. Cell Res. 2014, 323 (1), 87−99.
(24) Caetano-Pinto, P.; Janssen, M. J.; Gijzen, L.; Verscheijden, L.;
Wilmer, M. J.; Masereeuw, R. Fluorescence-Based Transport Assays
Revisited in a Human Renal Proximal Tubule Cell Line. Mol.
Pharmaceutics 2016, 13 (3), 933−44.
(25) Manohar, S.; Leung, N. Cisplatin nephrotoxicity: a review of the
literature. J. Nephrol. 2017, 1.
(26) Wilmer, M. J.; Saleem, M. A.; Masereeuw, R.; Ni, L.; van der
Velden, T. J.; Russel, F. G.; et al. Novel conditionally immortalized
human proximal tubule cell line expressing functional influx and efflux
transporters. Cell Tissue Res. 2010, 339 (2), 449−457.
(27) Koenderink, J. B.; Geibel, S.; Grabsch, E.; De Pont, J. J.; Bamberg,
E.; Friedrich, T. Electrophysiological analysis of the mutated Na,K-
ATPase cation binding pocket. J. Biol. Chem. 2003, 278 (51), 51213−
51222.
(28) Noe, G.; Bellesoeur, A.; Thomas-Schoemann, A.; Rangarajan, S.;
Naji, F.; Puszkiel, A.; Huillard, O.; Saidu, N.; Golmard, L.; Alexandre, J.;
et al. Clinical and kinomic analysis identifies peripheral blood
mononuclear cells as a potential pharmacodynamic biomarker in
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00308
Mol. Pharmaceutics 2017, 14, 2147−2157
2156
metastatic renal cell carcinoma patients treated with sunitinib.
Oncotarget. 2015, 7 (41), 67507−67520.
(29) Hilhorst, R.; Houkes, L.; Mommersteeg, M.; Musch, J.; van den
Berg, A.; Ruijtenbeek, R. Peptide microarrays for profiling of serine/
threonine kinase activity of recombinant kinases and lysates of cells and
tissue samples. Methods Mol. Biol. 2013, 977, 259−271.
(30) Lemeer, S.; Jopling, C.; Naji, F.; Ruijtenbeek, R.; Slijper, M.; Heck,
A. J.; et al. Protein-tyrosine kinase activity profiling in knock down
zebrafish embryos. PLoS One 2007, 2 (7), e581.
(31) den Boer, E.; Meesters, R. J.; van Zelst, B. D.; Luider, T. M.;
Hazes, J. M.; Heil, S. G.; et al. Measuringmethotrexate polyglutamates in
red blood cells: a new LC−MS/MS-based method. Anal. Bioanal. Chem.
2013, 405 (5), 1673−1681.
(32) Miller, R. P.; Tadagavadi, R. K.; Ramesh, G.; Reeves, W. B.
Mechanisms of Cisplatin nephrotoxicity. Toxins 2010, 2 (11), 2490−
2518.
(33) Holle, S. K.; Ciarimboli, G.; Edemir, B.; Neugebauer, U.;
Pavenstadt, H.; Schlatter, E. Properties and regulation of organic cation
transport in freshly isolated mouse proximal tubules analyzed with a
fluorescence reader-based method. Pfluegers Arch. 2011, 462 (2), 359−
369.
(34) Yang, S. L.; Zhao, F. Y.; Song, H.; Shen, D. Y.; Xu, X. J.
Methotrexate Associated Renal Impairment Is Related to Delayed
Elimination of High-Dose Methotrexate. Sci. World J. 2015, 2015,
751703.
(35) Hagos, Y.; Wolff, N. A. Assessment of the role of renal organic
anion transporters in drug-induced nephrotoxicity. Toxins 2010, 2 (8),
2055−2082.
(36) Yin, J.; Wang, J. Renal drug transporters and their significance in
drug-drug interactions. Acta Pharm. Sin. B 2016, 6 (5), 363−373.
(37) Schmeling, H.; Horneff, G.; Benseler, S. M.; Fritzler, M. J.
Pharmacogenetics: can genes determine treatment efficacy and safety in
JIA? Nat. Rev. Rheumatol. 2014, 10 (11), 682−690.
(38) Morrissey, K. M.; Stocker, S. L.; Wittwer, M. B.; Xu, L.;
Giacomini, K. M. Renal transporters in drug development. Annu. Rev.
Pharmacol. Toxicol. 2013, 53, 503−29.
(39) Melenhorst, W. B.; Mulder, G. M.; Xi, Q.; Hoenderop, J. G.;
Kimura, K.; Eguchi, S.; et al. Epidermal growth factor receptor signaling
in the kidney: key roles in physiology and disease.Hypertension 2008, 52
(6), 987−993.
(40) Ferguson, B. D.; Tan, Y. H.; Kanteti, R. S.; Liu, R.; Gayed, M. J.;
Vokes, E. E.; Ferguson, M. K.; Iafrate, A. J.; Gill, P. S.; Salgia, R.; et al.
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic
Pathway Analysis in Lung Cancer. Sci. Rep. 2015, 5, 10641.
(41) Zhang, Q.; Hong, M.; Duan, P.; Pan, Z.; Ma, J.; You, G. Organic
anion transporter OAT1 undergoes constitutive and protein kinase C-
regulated trafficking through a dynamin- and clathrin-dependent
pathway. J. Biol. Chem. 2008, 283 (47), 32570−32579.
(42) Barros, S. A.; Srimaroeng, C.; Perry, J. L.; Walden, R.; Dembla-
Rajpal, N.; Sweet, D. H.; et al. Activation of protein kinase Czeta
increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated trans-
port. J. Biol. Chem. 2009, 284 (5), 2672−2679.
(43) Li, S.; Zhang, Q.; You, G. Three ubiquitination sites of organic
anion transporter-1 synergistically mediate protein kinase C-dependent
endocytosis of the transporter.Mol. Pharmacol. 2013, 84 (1), 139−146.
(44) Xu, D.; Huang, H.; Toh, M. F.; You, G. Serum- and
glucocorticoid-inducible kinase sgk2 stimulates the transport activity
of human organic anion transporters 1 by enhancing the stability of the
transporter. Int. J. Biochem. Mol. Biol. 2016, 7 (1), 19−26.
(45) Soodvilai, S.; Chatsudthipong, A.; Chatsudthipong, V. Role of
MAPK and PKA in regulation of rbOCT2-mediated renal organic cation
transport. Am. J. Physiol. Renal Physiol. 2007, 293 (1), F21−F27.
(46) Sprowl, J. A.; Ong, S. S.; Gibson, A. A.; Hu, S.; Du, G.; Lin, W.;
et al. A phosphotyrosine switch regulates organic cation transporters.
Nat. Commun. 2016, 7, 10880.
(47) Xie, Y.; Nakanishi, T.; Natarajan, K.; Safren, L.; Hamburger, A.
W.; Hussain, A.; et al. Functional cyclic AMP response element in the
breast cancer resistance protein (BCRP/ABCG2) promoter modulates
epidermal growth factor receptor pathway- or androgen withdrawal-
mediated BCRP/ABCG2 transcription in human cancer cells. Biochim.
Biophys. Acta, Gene Regul. Mech. 2015, 1849 (3), 317−327.
(48) Wojtal, K. A.; de Vries, E.; Hoekstra, D.; van Ijzendoorn, S. C.
Efficient trafficking of MDR1/P-glycoprotein to apical canalicular
plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring
and glucosylceramide. Mol. Biol. Cell 2006, 17 (8), 3638−3650.
(49) Stegeman, H.; Kaanders, J. H.;Wheeler, D. L.; van der Kogel, A. J.;
Verheijen, M. M.; Waaijer, S. J.; Iida, M.; Grenman, R.; Span, P. N.;
Bussink, J. Activation of AKT by hypoxia: a potential target for hypoxic
tumors of the head and neck. BMC Cancer 2012, 12, 463.
(50) Nozaki, Y.; Kusuhara, H.; Kondo, T.; Hasegawa, M.; Shiroyanagi,
Y.; Nakazawa, H.; et al. Characterization of the uptake of organic anion
transporter (OAT) 1 and OAT3 substrates by human kidney slices. J.
Pharmacol. Exp. Ther. 2007, 321 (1), 362−369.
(51) Wang, L.; Sweet, D. H. Renal organic anion transporters (SLC22
family): expression, regulation, roles in toxicity, and impact on injury
and disease. AAPS J. 2013, 15 (1), 53−69.
(52) Fisher, D. A.; Salido, E. C.; Barajas, L. Epidermal growth factor
and the kidney. Annu. Rev. Physiol. 1989, 51, 67−80.
(53) Ahn, S. Y.; Nigam, S. K. Toward a systems level understanding of
organic anion and other multispecific drug transporters: a remote
sensing and signaling hypothesis. Mol. Pharmacol. 2009, 76 (3), 481−
490.
(54) Wu, W.; Dnyanmote, A. V.; Nigam, S. K. Remote communication
through solute carriers and ATP binding cassette drug transporter
pathways: an update on the remote sensing and signaling hypothesis.
Mol. Pharmacol. 2011, 79 (5), 795−805.
(55) Nigam, S. K. What do drug transporters really do? Nat. Rev. Drug
Discovery 2014, 14 (1), 29−44.
(56) Langan, T. J.; Chou, R. C. Synchronization of mammalian cell
cultures by serum deprivation. Methods Mol. Biol. 2011, 761, 75−83.
(57) Wada, Y.; Iyoda, M.; Matsumoto, K.; Shindo-Hirai, Y.; Kuno, Y.;
Yamamoto, Y.; et al. Epidermal growth factor receptor inhibition with
erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS
One 2014, 9 (11), e111728.
(58) Sacco, A. G.; Cohen, E. E. Current Treatment Options for
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J.
Clin. Oncol. 2015, 33 (29), 3305−13.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00308
Mol. Pharmaceutics 2017, 14, 2147−2157
2157
